Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis#
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942–8.PolanczykGde LimaMSHortaBLBiedermanJRohdeLA.The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry2007;164:942–8.10.1176/ajp.2007.164.6.94217541055Search in Google Scholar
Faraone S, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006;36:159–65.FaraoneSBiedermanJMickE.The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med2006;36:159–65.10.1017/S003329170500471X16420712Search in Google Scholar
Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20:17–37.GrahamJBanaschewskiTBuitelaarJCoghillDDanckaertsMDittmannRW, European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry2011;20:17–37.10.1007/s00787-010-0140-6301221021042924Search in Google Scholar
NICE. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. Leicester (UK): British Psychological Society (UK); 2009.NICE. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. Leicester (UK): British Psychological Society (UK); 2009.Search in Google Scholar
CADDRA. Canadian ADHD Practice Guidelines (CAP-Guidelines), Third edition. Canadian ADHD Resource Alliance; 2011. Available at: www.caddra.ca.CADDRA. Canadian ADHD Practice Guidelines (CAP-Guidelines), Third edition. Canadian ADHD Resource Alliance; 2011. Available at: www.caddra.ca.Search in Google Scholar
AACAP. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894–921.AACAP. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry2007;46:894–921.10.1097/chi.0b013e318054e72417581453Search in Google Scholar
Hodgkins P, Sasané R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther 2011;33:188–203.HodgkinsPSasanéRMeijerWM.Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther2011;33:188–203.10.1016/j.clinthera.2011.03.00121497704Search in Google Scholar
Efron D, Davies S, Sciberras E. Current Australian pediatric practice in the assessment and treatment of ADHD. Acad Pediatr 2013;13:328–33.EfronDDaviesSSciberrasE.Current Australian pediatric practice in the assessment and treatment of ADHD. Acad Pediatr2013;13:328–33.10.1016/j.acap.2013.03.00923830018Search in Google Scholar
Renoux C, Shin J-Y, Dell’Aniello S, Fergusson E, Suissa S. Prescribing trends of attention-deficit hyperactivity disorder (adhd) medications in UK primary care, 1995-2015. Br J Clin Pharmacol 2016;82:858–68.RenouxCShinJ-YDell’AnielloSFergussonESuissaS.Prescribing trends of attention-deficit hyperactivity disorder (adhd) medications in UK primary care, 1995-2015. Br J Clin Pharmacol2016;82:858–68.10.1111/bcp.13000533811527145886Search in Google Scholar
Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: Evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 2009;39:179–95.Van OsJLinscottRJMyin-GermeysIDelespaulPKrabbendamL.A systematic review and meta-analysis of the psychosis continuum: Evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med2009;39:179–95.10.1017/S003329170800381418606047Search in Google Scholar
Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009;123:611–6.MosholderADGelperinKHammadTAPhelanKJohann-LiangR.Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics2009;123:611–6.10.1542/peds.2008-018519171629Search in Google Scholar
NICE. Attention deficit hyperactivity disorder (ADHD): Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. NICE; 2014. Available at: https://www.nice.org.uk/guidance/cg72.NICE. Attention deficit hyperactivity disorder (ADHD): Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. NICE; 2014. Available at: https://www.nice.org.uk/guidance/cg72.Search in Google Scholar
FDA. Highlights of prescribing information, Concerta®. 2015. Available at: www.fda.gov; http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021121s015s017lbl.pdf.FDA. Highlights of prescribing information, Concerta®. 2015. Available at: www.fda.gov; http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021121s015s017lbl.pdf.Search in Google Scholar
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013;54:227–46.CorteseSHoltmannMBanaschewskiTBuitelaarJCoghillDDanckaertsM, Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry2013;54:227–46.10.1111/jcpp.1203623294014Search in Google Scholar
Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006;163:1149–52.RossRG.Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry2006;163:1149–52.10.1176/ajp.2006.163.7.1149Search in Google Scholar
Mosholder A. Psychiatric adverse events in clinical trials of drugs for ADHD. FDA Report PID D060163. US Food and Drug Administration; 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_10_01_Mosholder.pdf.MosholderA. Psychiatric adverse events in clinical trials of drugs for ADHD. FDA Report PID D060163. US Food and Drug Administration; 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_10_01_Mosholder.pdf.Search in Google Scholar
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.LundhALexchinJMintzesBSchrollJBBeroL.Industry sponsorship and research outcome. Cochrane Database Syst Rev2017;2:MR000033.10.1002/14651858.MR000033.pub3813249228207928Search in Google Scholar
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 2015;1:CD009885.StorebøOJRamstadEKroghHBNilausenTDSkoogMHolmskovM, Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev2015;1:CD009885.10.1002/14651858.CD009885.pub2876335126599576Search in Google Scholar
Storebø OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 2015;351:h5203StorebøOJKroghHBRamstadEMoreira-MaiaCRHolmskovMSkoogM, Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ2015;351:h520310.1136/bmj.h5203465941426608309Search in Google Scholar
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies. [in press].StorebøOJPedersenNRamstadEKielsholmMLNielsenSSKroghHB, Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies. [in press].Search in Google Scholar
Higgins J, Green S (Eds.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. Cochrane Collaboration; 2011. Available at: www.cochrane-www.handbook.org.HigginsJGreenS (Eds.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. Cochrane Collaboration; 2011. Available at: www.cochrane-www.handbook.org.Search in Google Scholar
Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.LiberatiAAltmanDTetzlaffJMulrowCGotzschePIoannidisJ, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700.10.1136/bmj.b2700271467219622552Search in Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group T. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.MoherDLiberatiATetzlaffJAltmanDG, PRISMA Group T. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009; 6:e1000097.10.1371/journal.pmed.1000097270759919621072Search in Google Scholar
Storebø OJ, Rosendal S, Skoog M, Groth C, Bille T, Buch Rasmussen K, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2012;5.StorebøOJRosendalSSkoogMGrothCBilleTBuch RasmussenK, Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev2012;5.10.1002/14651858.CD009885Search in Google Scholar
Storebø OJ, Pedersen N, Ramstad E, Krogh HB, Moreira-Maia CR, Magnusson FL, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents -assessment of harmful effects in non-randomised studies. Cochrane Database Syst Rev 2016;2:CD012069.StorebøOJPedersenNRamstadEKroghHBMoreira-MaiaCRMagnussonFL, Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents -assessment of harmful effects in non-randomised studies. Cochrane Database Syst Rev2016;2:CD012069.10.1002/14651858.CD012069Search in Google Scholar
Pelham WE. Pharmacotherapy of children with attention-deficit hyperactivity disorder. School Psychol Rev 1993;22:199–227.PelhamWE.Pharmacotherapy of children with attention-deficit hyperactivity disorder. School Psychol Rev1993;22:199–227.10.1080/02796015.1993.12085647Search in Google Scholar
Gluud L, Thorlund K, Gluud C, Woods L, Harris R, Sterne J. Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2008;149:219.GluudLThorlundKGluudCWoodsLHarrisRSterneJ.Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med2008;149:219.10.7326/0003-4819-149-3-200808050-00023Search in Google Scholar
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982–9.KjaergardLLVillumsenJGluudC.Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med2001;135:982–9.10.7326/0003-4819-135-11-200112040-00010Search in Google Scholar
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609–13.MoherDPhamBJonesACookDJJadadARMoherM, Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352:609–13.10.1016/S0140-6736(98)01085-XSearch in Google Scholar
Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012;157:429–38.SavovićJJonesHEAltmanDGHarrisRJJüniPPildalJ, Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med2012;157:429–38.10.7326/0003-4819-157-6-201209180-0053722945832Search in Google Scholar
Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012;16:1–82.SavovićJJonesHAltmanDHarrisRJűniPPildalJ, Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess2012;16:1–82.10.3310/hta1635022989478Search in Google Scholar
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408–12.SchulzKFChalmersIHayesRJAltmanDG.Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408–12.10.1001/jama.1995.03520290060030Search in Google Scholar
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601–5.WoodLEggerMGluudLLSchulzKFJüniPAltmanDG, Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336:601–5.10.1136/bmj.39465.451748.AD226799018316340Search in Google Scholar
Sterne J, Hernán M, Reeves B, Savović J, Berkman N, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomized studies of interventions. BMJ 2016; 355:i4919.SterneJHernánMReevesBSavovićJBerkmanNViswanathanM, ROBINS-I: A tool for assessing risk of bias in non-randomized studies of interventions. BMJ2016; 355:i4919.10.1136/bmj.i4919506205427733354Search in Google Scholar
Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719–25.AndrewsJGuyattGOxmanADAldersonPDahmPFalck-YtterY, GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol2013;66:719–25.10.1016/j.jclinepi.2012.03.01323312392Search in Google Scholar
Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol 2014;14:120.JakobsenJCWetterslevJWinkelPLangeTGluudC.Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol2014;14:120.10.1186/1471-2288-14-120425184825416419Search in Google Scholar
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008;61:763–9.BrokJThorlundKGluudCWetterslevJ.Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol2008;61:763–9.10.1016/j.jclinepi.2007.10.00718411040Search in Google Scholar
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008;61:64–75.WetterslevJThorlundKBrokJGluudC.Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol2008;61:64–75.10.1016/j.jclinepi.2007.03.01318083463Search in Google Scholar
Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 2017;17:39.WetterslevJJakobsenJCGluudC.Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol2017;17:39.10.1186/s12874-017-0315-7539770028264661Search in Google Scholar
Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research. 2011. pp. 1–115. Available at: www.ctu.dk/tsa.ThorlundKEngstrømJWetterslevJBrokJImbergerGGluudC. User manual for trial sequential analysis (TSA). Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research. 2011. pp. 1–115. Available at: www.ctu.dk/tsa.Search in Google Scholar
Biostat. Comprehensive meta-analysis [computer program]. Version 2. 2008. Available at: https://www.meta-analysis.com/pages/demo.php.Biostat. Comprehensive meta-analysis [computer program]. Version 2. 2008. Available at: https://www.meta-analysis.com/pages/demo.php.Search in Google Scholar
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2012. Available at: http://community.cochrane.org/tools/review-production-tools/revman-5.The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2012. Available at: http://community.cochrane.org/tools/review-production-tools/revman-5.Search in Google Scholar
Inglis SK, Carucci S, Garas P, Hage A, Banaschewski T, Buitelaar JK, et al. Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. BMJ Open 2016;6:e010433.InglisSKCarucciSGarasPHageABanaschewskiTBuitelaarJK, Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. BMJ Open2016;6:e010433.10.1136/bmjopen-2015-010433485397327118284Search in Google Scholar
Clinicaltrials.gov. NCT02638168, Baweja R. Effects of evening dose of immediate release methylphenidate on sleep in children with ADHD. clinicaltrials.gov. 2015 Dec 18.Clinicaltrials.gov. NCT02638168, BawejaR.Effects of evening dose of immediate release methylphenidate on sleep in children with ADHD. clinicaltrials.gov. 2015Dec18.Search in Google Scholar
Childress AC, Spencer T, Lopez F, Gerstner O, Thulasiraman A, Muniz R, et al. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:351–61.ChildressACSpencerTLopezFGerstnerOThulasiramanAMunizR, Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol2009;19:351–61.10.1089/cap.2009.000719702487Search in Google Scholar
Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Ame Acad Child Adolesc Psychiatry 2008;47:180–8.PalumboDRSalleeFRPelhamWEBuksteinOGDavissWBMcDermottMP.Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Ame Acad Child Adolesc Psychiatry2008;47:180–8.10.1097/chi.0b013e31815d9af718182963Search in Google Scholar
Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham J, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008;47:189–98.DavissWBPatelNCRobbASMcDermottMPBuksteinOGPelhamJ, Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry2008;47:189–98.10.1097/chi.0b013e31815d9ae418182964Search in Google Scholar
Green T, Weinberger R, Diamond A, Berant M, Hirschfeld L, Frisch A, et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol 2011;21:589–95.GreenTWeinbergerRDiamondABerantMHirschfeldLFrischA, The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol2011;21:589–95.10.1089/cap.2011.004222149470Search in Google Scholar
Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry 2011;50:903–14.RiggsPDWinhusenTDaviesRDLeimbergerJDMikulich-GilbertsonSKleinC, Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry2011;50:903–14.10.1016/j.jaac.2011.06.010316479721871372Search in Google Scholar
Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. J Child Psychol Psychiatry 1996;37:587–95.BuitelaarJKvan der GaagRJSwaab-BarneveldHKuiperM.Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. J Child Psychol Psychiatry1996;37:587–95.10.1111/j.1469-7610.1996.tb01445.x8807439Search in Google Scholar
Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, et al. A comparison of morning-only and morning/late afternoon adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999;104:1300–11.PelhamWEGnagyEMChronisAMBurrows-MacLeanLFabianoGAOnyangoAN, A comparison of morning-only and morning/late afternoon adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics1999;104:1300–11.10.1542/peds.104.6.130010585981Search in Google Scholar
Pelham WE, Manos MJ, Ezzell CE, Tresco KE, Gnagy EM, Hoffman MT, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005; 44:522–9.PelhamWEManosMJEzzellCETrescoKEGnagyEMHoffmanMT, A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry2005; 44:522–9.10.1097/01.chi.0000157548.48960.9515908834Search in Google Scholar
Schachar R, Ickowicz A, Crosbie J, Donnelly GAE, Reiz JL, Miceli PC, et al. Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008;18:11–24.SchacharRIckowiczACrosbieJDonnellyGAEReizJLMiceliPC, Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol2008;18:11–24.10.1089/cap.2007.003918294084Search in Google Scholar
Waxmonsky J, Pelham WE, Gnagy E, Cummings MR, O’Connor B, Majumdar A, et al. The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. J Child Adolesc Psychopharmacol 2008;18:573–88.WaxmonskyJPelhamWEGnagyECummingsMRO’ConnorBMajumdarA, The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. J Child Adolesc Psychopharmacol2008;18:573–88.10.1089/cap.2008.065268009519108662Search in Google Scholar
Becker SP, Froehlich TE, Epstein JN. Effects of methylphenidate on sleep functioning in children with attention-deficit/hyperactivity disorder. J Devel Behav Pediatr 2016;37:395–404.BeckerSPFroehlichTEEpsteinJN.Effects of methylphenidate on sleep functioning in children with attention-deficit/hyperactivity disorder. J Devel Behav Pediatr2016;37:395–404.10.1097/DBP.0000000000000285488734627011002Search in Google Scholar
Froehlich T, Antonini T, Brinkman W, Langberg J, Simon J, Adams R, et al. Mediators of methylphenidate effects on math performance in children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2014;35:100–7.FroehlichTAntoniniTBrinkmanWLangbergJSimonJAdamsR, Mediators of methylphenidate effects on math performance in children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr2014;35:100–7.10.1097/DBP.0000000000000025392879724509055Search in Google Scholar
Ashkenasi A. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. Pediatr Neurol 2011;45:381–6.AshkenasiA.Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. Pediatr Neurol2011;45:381–6.10.1016/j.pediatrneurol.2011.09.00322115000Search in Google Scholar
Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BSG, et al. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. J Child Adolesc Psychopharmacol 2015;25:1.ArnoldLEGadowKDFarmerCAFindlingRLBuksteinOMolinaBSG, Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. J Child Adolesc Psychopharmacol2015;25:1.10.1089/cap.2014.0104440322425885010Search in Google Scholar
Baweja R, Belin PJ, Humphrey HH, Babocsai L, Pariseau ME, Waschbusch DA, et al. The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit/hyperactivity disorder and disruptive mood dysregulation disorder across home and school. J Child Adolesc Psychopharmacol 2016;26:154–63.BawejaRBelinPJHumphreyHHBabocsaiLPariseauMEWaschbuschDA, The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit/hyperactivity disorder and disruptive mood dysregulation disorder across home and school. J Child Adolesc Psychopharmacol2016;26:154–63.10.1089/cap.2015.0053480038226771437Search in Google Scholar
Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry 1999;44:811–3.CherlandEFitzpatrickR.Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry1999;44:811–3.10.1177/07067437990440081010566114Search in Google Scholar
Cortese S, Panei P, Arcieri R, Germinario EAP, Capuano A, Margari L, et al. Safety of methylphenidate and atomoxetine in children with attention-deficit/hyperactivity disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs 2015;29:21.CorteseSPaneiPArcieriRGerminarioEAPCapuanoAMargariL, Safety of methylphenidate and atomoxetine in children with attention-deficit/hyperactivity disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29:21.10.1007/s40263-015-0266-726293742Search in Google Scholar
Didoni A, Sequi M, Panei P, Bonati M, Lombardy ADHD Registry Group T. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. Eur J Clin Pharmacol 2011;67:1061–7.DidoniASequiMPaneiPBonatiM, Lombardy ADHD Registry Group T. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. Eur J Clin Pharmacol2011;67:1061–7.10.1007/s00228-011-1050-321538145Search in Google Scholar
Elman I, Sigler M, Kronenberg J, Lindenmayer JP, Doron A, Mendlovic S, et al. Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder (ADHD). Isr J Psychiatry Relat Sci 1998;35:280–6.ElmanISiglerMKronenbergJLindenmayerJPDoronAMendlovicS, Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder (ADHD). Isr J Psychiatry Relat Sci1998;35:280–6.Search in Google Scholar
Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Therap 2009;31:1844–55.FindlingRLWigalSBBuksteinOGBoellnerSWAbikoffHBTurnbowJM, Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Therap2009;31:1844–55.10.1016/j.clinthera.2009.08.00219808143Search in Google Scholar
Lee M-S, Lee SI, Hong SD, Kim J-H, Choi J, Joung Y-S. Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: A 12-week multicenter, open-label study. J Child Adolesc Psychopharmacol 2013;23:22–7.LeeM-SLeeSIHongSDKimJ-HChoiJJoungY-S.Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: A 12-week multicenter, open-label study. J Child Adolesc Psychopharmacol2013;23:22–7.10.1089/cap.2012.001823347125Search in Google Scholar
Na K-S, Lee SI, Hong SD, Kim J-H, Shim S-H, Choi J, et al. Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: An open-label study. Int Clin Psychopharmacol 2013;28:184–92.NaK-SLeeSIHongSDKimJ-HShimS-HChoiJ, Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: An open-label study. Int Clin Psychopharmacol2013;28:184–92.Search in Google Scholar
MacKenzie LE, Abidi S, Fisher HL, Propper L, Bagnell A, Morash-Conway J, et al. Stimulant medication and psychotic symptoms in offspring of parents with mental illness. Pediatrics 2016;137.MacKenzieLEAbidiSFisherHLPropperLBagnellAMorash-ConwayJ, Stimulant medication and psychotic symptoms in offspring of parents with mental illness. Pediatrics2016;137.10.1542/peds.2015-248626719291Search in Google Scholar
Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, et al. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry 2016;6:e956.ManKKCCoghillDChanEWLauWCYHollisCLiddleE, Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry2016;6:e956.10.1038/tp.2016.216531412827845780Search in Google Scholar
Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: A pilot double-blind randomized trial. J Clin Pharm Ther 2004;29:139–44.MohammadiMRKashaniLAkhondzadehSIzadianESOhadiniaS.Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: A pilot double-blind randomized trial. J Clin Pharm Ther2004;29:139–44.10.1111/j.1365-2710.2004.00545.x15068402Search in Google Scholar
Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 2005;14:297–304.RemschmidtHHoarePEttrichCRothenbergerASantoshPSchmidtM, Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry2005;14:297–304.10.1007/s00787-005-0467-616220213Search in Google Scholar
Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, et al. 12-Month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005;14:305–9.HoarePRemschmidtHMedoriREttrichCRothenbergerASantoshP, 12-Month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry2005;14:305–9.10.1007/s00787-005-0486-316220214Search in Google Scholar
Shyu Y-C, Yuan S-S, Lee S-Y, Yang C-J, Yang K-C, Lee T-L, et al. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. Schizophr Res 2015;168:161–7.ShyuY-CYuanS-SLeeS-YYangC-JYangK-CLeeT-L, Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. Schizophr Res2015;168:161–7.10.1016/j.schres.2015.08.03326363968Search in Google Scholar
Su Y, Li H, Chen Y, Fang F, Xu T, Lu H, et al. Remission rate and functional outcomes during a 6-month treatment with osmotic-release oral-system methylphenidate in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2015;35:12.SuYLiHChenYFangFXuTLuH, Remission rate and functional outcomes during a 6-month treatment with osmotic-release oral-system methylphenidate in children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol2015;35:12.10.1097/JCP.000000000000038926267421Search in Google Scholar
Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005;44:1015–23.WilensTMcBurnettKSteinMLernerMSpencerTWolraichM.ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry2005;44:1015–23.10.1097/01.chi.0000173291.28688.e716175106Search in Google Scholar
Aguilera-Albesa S, Yoldi-Petri ME, Molins-Castiella T, Dura-Trave T. Hallucinations caused by the introduction of methylphenidate at low doses [Spanish]. Rev Neurologia 2010; 51:254–5.Aguilera-AlbesaSYoldi-PetriMEMolins-CastiellaTDura-TraveT.Hallucinations caused by the introduction of methylphenidate at low doses [Spanish]. Rev Neurologia2010; 51:254–5.Search in Google Scholar
Coignoux Y, Estingoy P, Bastard A. From hyperactivity to schizophrenia? Clinical, neurobiological and therapeutic discussion of a case. [French]. Ann Médico-Psychologiques (Paris) 2009:57–65.CoignouxYEstingoyPBastardA.From hyperactivity to schizophrenia? Clinical, neurobiological and therapeutic discussion of a case. [French]. Ann Médico-Psychologiques (Paris)2009:57–65.10.1016/j.amp.2008.11.006Search in Google Scholar
Fernandez-Fernandez MA, Rufo-Campos M, Mateos-Checa R, Munoz-Cabello B, Madruga-Garrido M, Blanco-Martinez B. Childhood psychosis secondary to methylphenidate [Spanish]. Rev Neurologia 2011; 52:446–7.Fernandez-FernandezMARufo-CamposMMateos-ChecaRMunoz-CabelloBMadruga-GarridoMBlanco-MartinezB.Childhood psychosis secondary to methylphenidate [Spanish]. Rev Neurologia2011; 52:446–7.Search in Google Scholar
Goetz M, Prihodova I, Hrdlicka M. Long lasting complex nocturnal hallucinations during Osmotic Release Oral System (OROS) methylphenidate treatment in a 7-year old girl. Neuroendocrinol Letters 2011;32:619–22.GoetzMPrihodovaIHrdlickaM.Long lasting complex nocturnal hallucinations during Osmotic Release Oral System (OROS) methylphenidate treatment in a 7-year old girl. Neuroendocrinol Letters2011;32:619–22.Search in Google Scholar
Gross-Tsur V, Joseph A, Shalev RS. Hallucinations during methylphenidate therapy. Neurology 2004;63:753–4.Gross-TsurVJosephAShalevRS.Hallucinations during methylphenidate therapy. Neurology2004;63:753–4.10.1212/01.WNL.0000134656.93147.F1Search in Google Scholar
Halevy A, Shuper A. Methylphenidate induction of complex visual hallucinations. J Child Neurology 2009; 24:1005–7.HalevyAShuperA.Methylphenidate induction of complex visual hallucinations. J Child Neurology2009; 24:1005–7.10.1177/088307380833135719502578Search in Google Scholar
Porfirio MC, Giana G, Giovinazzo S, Curatolo P. Methylphenidate-induced visual hallucinations. Neuropediatrics 2011;42:30–1.PorfirioMCGianaGGiovinazzoSCuratoloP.Methylphenidate-induced visual hallucinations. Neuropediatrics2011;42:30–1.10.1055/s-0031-127573821500140Search in Google Scholar
Rashid J, Mitelman S. Methylphenidate and somatic hallucinations. J Am Acad Child Adolesc Psychiatry 2007;46:945–6.RashidJMitelmanS.Methylphenidate and somatic hallucinations. J Am Acad Child Adolesc Psychiatry2007;46:945–6.10.1097/CHI.0b013e318067fd7c17667474Search in Google Scholar
Shibib S, Chalhoub N. Stimulant induced psychosis. Child Adolesc Ment Health 2009;14:20–3.ShibibSChalhoubN.Stimulant induced psychosis. Child Adolesc Ment Health2009;14:20–3.10.1111/j.1475-3588.2008.00490.xSearch in Google Scholar
Tomás Vila M, Izquierdo Quevedo FJ, Cerdán Vera MT, Fernández A, Artés Figueres M, Revert Gomas M. Visual hallucinations caused by methylphenidate [Spanish]. An Pediatr 2010;72:229–30.Tomás VilaMIzquierdo QuevedoFJCerdán VeraMTFernándezAArtés FigueresMRevert GomasM.Visual hallucinations caused by methylphenidate [Spanish]. An Pediatr2010;72:229–30.10.1016/j.anpedi.2009.10.01320097145Search in Google Scholar
Brown University. Somatic hallucinations with methylphenidate in a 10-year-old boy [Case report]. The Brown University Child & Adolesc Psychopharmacol Update 2007;9:11.Brown University. Somatic hallucinations with methylphenidate in a 10-year-old boy [Case report]. The Brown University Child & Adolesc Psychopharmacol Update2007;9:11.Search in Google Scholar
Irmak A, Ince-Tasdelen B, Ozmen S, Oztop D. Treatment choice in association of attention deficit-hyperactivity disorder with Williams and Moebius Syndromes: Case reports. Klinik Psikofarmakoloji Bülteni 2014;24:226.IrmakAInce-TasdelenBOzmenSOztopD.Treatment choice in association of attention deficit-hyperactivity disorder with Williams and Moebius Syndromes: Case reports. Klinik Psikofarmakoloji Bülteni2014;24:226.Search in Google Scholar
Herguner S, Ozayhan HY. Visual hallucinations with methylphenidate and acetaminophen in combination. J Child Adolesc Psychopharmacol 2015;25:598–9.HergunerSOzayhanHY.Visual hallucinations with methylphenidate and acetaminophen in combination. J Child Adolesc Psychopharmacol2015;25:598–9.10.1089/cap.2015.005726222326Search in Google Scholar
Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 2012;42:1857–63.KelleherIConnorDClarkeMCDevlinNHarleyMCannonM.Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med2012;42:1857–63.10.1017/S003329171100296022225730Search in Google Scholar
Kelleher I, Harley M, Murtagh A, Cannon M. Are screening instruments valid for psychotic-like experiences? A validation study of screening questions for psychotic-like experiences using in-depth clinical interview. Schizophr Bull 2011;37:362–69.KelleherIHarleyMMurtaghACannonM.Are screening instruments valid for psychotic-like experiences? A validation study of screening questions for psychotic-like experiences using in-depth clinical interview. Schizophr Bull2011;37:362–69.10.1093/schbul/sbp057304461719542527Search in Google Scholar
Dalsgaard S, Mortensen PB, Frydenberg M, Maibing CM, Nordentoft M, Thomsen PH. Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood. Eur Psychiatry 2014;29:259–63.DalsgaardSMortensenPBFrydenbergMMaibingCMNordentoftMThomsenPH.Association between attention-deficit hyperactivity disorder in childhood and schizophrenia later in adulthood. Eur Psychiatry2014;29:259–63.10.1016/j.eurpsy.2013.06.00424016863Search in Google Scholar
Hamshere ML, Stergiakouli E, Langley K, Martin J, Holmans P, Kent L, et al. Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry 2013;203:107–11.HamshereMLStergiakouliELangleyKMartinJHolmansPKentL, Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry2013;203:107–11.10.1192/bjp.bp.112.117432373011423703318Search in Google Scholar
Carroll LS, Kendall K, O’Donovan MC, Owen MJ, Williams NM. Evidence that putative ADHD low risk alleles at SNAP25 may increase the risk of schizophrenia. Am J Med Genet Part B Neuropsychiatr Genet 2009;150B:893–9.CarrollLSKendallKO’DonovanMCOwenMJWilliamsNM.Evidence that putative ADHD low risk alleles at SNAP25 may increase the risk of schizophrenia. Am J Med Genet Part B Neuropsychiatr Genet2009;150B:893–9.10.1002/ajmg.b.3091519132710Search in Google Scholar
Engert V, Pruessner JC. Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Curr Neuropharmacol 2008;6:322–8.EngertVPruessnerJC.Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Curr Neuropharmacol2008;6:322–8.10.2174/157015908787386069270128519587853Search in Google Scholar
Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 2012;3:1–11.SchwartzTLSachdevaSStahlSM.Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol2012;3:1–11.10.3389/fphar.2012.00195350586123189055Search in Google Scholar
